Transition pathways to INVEGA HAFYERA^® from INVEGA SUSTENNA^® or INVEGA TRINZA^®

Video transcript

Speaker 1:

Navigating Long-Acting Injectable Conversations to Achieve Longer Dosing Intervals in Adult Patients with Schizophrenia, a virtual national broadcast for pharmacists in mental health. This video was developed from virtual sessions previously recorded in June 2022. Any audience participation and/or interactivity will not be enabled or be available as part of this presentation. Our guest speaker is Dr. Alberto Augsten, pharmacy clinical manager and board-certified clinical toxicologist at Memorial Regional Hospital in Hollywood, Florida.

Alberto Augsten:

As Mary said, let's go ahead and begin this very interesting discussion on navigating long-acting injectable conversations to achieve longer dosing intervals in adult patients with schizophrenia. So once again, thank you and welcome to the program. It must be stated this is a promotional educational activity brought to you by Janssen. It's not certified for continuing medical education. I am a paid speaker for Janssen, and we're presenting on behalf of Janssen and must present information in compliance with the FDA.

Now let's go ahead and transition, and we're going to show some information pertaining specifically to INVEGA HAFYERA^®. Like I mentioned, once we initiated INVEGA SUSTENNA^®. Now let's talk about INVEGA HAFYERA^®. Two ways to get there. These are what are known as the transition pathways.

In front of you, the first one, on the top left, is INVEGA SUSTENNA^®. Patients receiving INVEGA SUSTENNA^® who have been adequately treated for at least four months with the last two doses being the same, if they happen to be on a moderate or high dose, 156 mg or 234 mg, the pathway is as follows. To the right, they can go directly into INVEGA HAFYERA^® into the gluteal muscle at the next scheduled INVEGA SUSTENNA^® dose, and there's a plus-or-minus seven-day window, and the respective dose is 1,092 and 1,560 mg. Or individuals can go from INVEGA SUSTENNA^®, once they have four months stable, into the INVEGA TRINZA^® pathway, respectively 546 mg and 819 for moderate and high dose. There's a plus-or-minus seven-day window as well. And on the following INVEGA TRINZA^® dose that's due, the patient can receive INVEGA HAFYERA^®, moderate or high dose. The one difference here in the timeframe, as you can see in parentheses, is a plus-or-minus 14-day window if going from INVEGA TRINZA^® to INVEGA HAFYERA^®.

Now, very important: We've discussed many things. We've talked about achieving longer dosing intervals for adult patients with schizophrenia with the Janssen Neuroscience LAIs. Two treatment pathways to get to INVEGA HAFYERA^®. It all starts with INVEGA SUSTENNA^®. INVEGA SUSTENNA^®, after four months, with the last two doses being the same, specifically the moderate and high, 156 and 234, and transitioning straight to INVEGA HAFYERA^®. Or they're on to INVEGA TRINZA^® and at least one dose cycle, and then transitioning on to INVEGA HAFYERA^® like we mentioned earlier.

Pharmacists could play a key role in facilitating the transition of patients to longer dosing intervals. It's important here, proving access to LEI is convenient for many patients through LAI administrations in pharmacies and clinics. And I know many of the folks on the line are involved in this now, involved in seeing these patients, administering these products, educating on these products, and then facilitating smooth transitions of care through increased communication amongst inpatient and outpatient pharmacists, very important to the care of our patients in the community.

With that being said, the first and only LAI that can be given every six months for adult patients with schizophrenia who have been adequately treated with INVEGA SUSTENNA^® for four months and adequately treated with INVEGA TRINZA^® for at least a three-month injection cycle, which is INVEGA HAFYERA^®.